254 related articles for article (PubMed ID: 25457974)
21. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
22. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
Massari F; Ciccarese C; Santoni M; Lopez-Beltran A; Scarpelli M; Montironi R; Cheng L
Expert Rev Anticancer Ther; 2015; 15(12):1367-9. PubMed ID: 26568023
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
[TBL] [Abstract][Full Text] [Related]
25. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.
Meteoglu I; Erdogdu IH; Meydan N; Erkus M; Barutca S
J Exp Clin Cancer Res; 2008 Oct; 27(1):53. PubMed ID: 18928570
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
Braga MS; Turaça TL; Foguer K; Chaves KC; Pesquero JB; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2013 Jul; 67(6):511-5. PubMed ID: 23726969
[TBL] [Abstract][Full Text] [Related]
27. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
28. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
30. Precision medicine for metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
[TBL] [Abstract][Full Text] [Related]
31. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
32. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma.
Wu L; Li X; Ye L; Shayiremu D; Deng X; Zhang X; Jiang W; Yang Y; Gong K; Zhang N
Anticancer Res; 2014 Feb; 34(2):715-22. PubMed ID: 24511004
[TBL] [Abstract][Full Text] [Related]
34. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
35. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
36. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
37. [Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma].
Chang BD; Cao LS; Zhou HL
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):687-90. PubMed ID: 20021866
[TBL] [Abstract][Full Text] [Related]
38. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
39. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
40. [Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]